Segment Data

6 Months Ended

Jun. 30, 2023

Segment Data

Segment Data

13. Segment Data

The Company has two reportable segments-human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing human products and the ongoing

commercialization of Mytesi, which the U.S. FDA approves for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

The Company's reportable segments net revenues and net loss for the three and six months ended June 30, 2023 and 2022 consisted of the following:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
(in thousands)	2023		2022		2023		2022
Revenue from external customers
Human Health	$	2,627	$	2,819	$	4,553	$	5,380
Animal Health		49		102		95		166
Consolidated Totals	$	2,676	$	2,921	$	4,648	$	5,546
Segment net loss
Human Health	$	(4,576)	$	372	$	(11,115)	$	(9,596)
Animal Health		(7,715)		(9,762)		(13,573)		(17,958)
Consolidated Totals	$	(12,291)	$	(9,390)	$	(24,688)	$	(27,554)

The Company's reportable segments assets consisted of the following:

	June 30,		December 31,
	2023		2022
(in thousands)	(unaudited)
Segment assets
Human Health	$	40,819	$	40,898
Animal Health		145,152		128,607
Total	$	185,971	$	169,505

The reconciliation of segments assets to the consolidated assets is as follows:

	June 30,		December 31,
(in thousands)	2023		2022
	(unaudited)
Total assets for reportable segments	$	185,971	$	169,505
Less: Investment in subsidiary		(29,232)		(29,232)
Less: Intercompany loan		(104,567)		(92,821)
Consolidated Totals	$	52,172	$	47,452